ClinicalTrials.Veeva
Menu

Find clinical trials for Endometrial Cancer in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Ovarian Cancer
Breast Cancer
Triple Negative Breast Cancer
Ovarian Epithelial Carcinoma
Colorectal Cancer

Endometrial Cancer trials near Philadelphia, PA, USA:

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial...

Enrolling
Endometrial Cancer
Drug: Serabelisib
Drug: Paclitaxel

Phase 2

Faeth Therapeutics

Doylestown, Pennsylvania, United States and 13 other locations

letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until eit...

Active, not recruiting
Endometrial Cancer
Drug: Letrozole
Drug: Abemaciclib

Phase 2

Gynecologic Oncology Group (GOG)

Willow Grove, Pennsylvania, United States and 28 other locations

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when com...

Enrolling
Endometrial Cancer
Drug: Carboplatin
Drug: Paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Abington, Pennsylvania, United States and 210 other locations

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...

Enrolling
Endometrial Cancer
Drug: Paclitaxel
Drug: Nab-paclitaxel

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Philadelphia, Pennsylvania, United States and 241 other locations

(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...

Active, not recruiting
Endometrial Neoplasms
Drug: Carboplatin
Biological: durvalumab

Phase 3

AstraZeneca
AstraZeneca

Camden, New Jersey, United States and 202 other locations

participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....

Active, not recruiting
Neoplasms
Drug: Paclitaxel
Drug: Carboplatin

Phase 3

Tesaro
Tesaro

Philadelphia, Pennsylvania, United States and 168 other locations

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer...

Enrolling
Endometrial Cancer
Drug: Paclitaxel
Drug: Sacituzumab govitecan-hziy

Phase 3

Gilead Sciences
Gilead Sciences

Philadelphia, Pennsylvania, United States and 161 other locations

This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer...

Active, not recruiting
Refractory Endometrial Clear Cell Adenocarcinoma
Refractory Endometrial Undifferentiated Carcinoma
Other: Questionnaire Administration
Diagnostic Test: Progesterone Receptor Positive ( PGR Positive; PR Positive)

Phase 2

Thomas Jefferson University
Thomas Jefferson University

Philadelphia, Pennsylvania, United States and 1 other location

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in...

Active, not recruiting
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Endometrial Cancer
Biological: vudalimab

Phase 2

Xencor
Xencor

Philadelphia, Pennsylvania, United States and 16 other locations

To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial c...

Active, not recruiting
Endometrial Cancer
Uterine Carcinosarcoma
Drug: Bevacizumab
Drug: Atezolizumab

Phase 2

Medical College of Wisconsin
Medical College of Wisconsin

Bethlehem, Pennsylvania, United States and 2 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems